Skip to content

Effect of Different VV ECMO Flows on Lung Perfusion Monitored by EIT

Effect of Different VV ECMO Flows on Lung Perfusion Monitored by EIT: an Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05778292
Enrollment
15
Registered
2023-03-21
Start date
2023-01-01
Completion date
2024-12-31
Last updated
2023-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness

Keywords

VV ECMO, EIT, Lung perfusion

Brief summary

The purpose of this study is to investigate the feasibility of using electric impedance tomography (EIT) to monitor lung perfusion during veno-venous (VV) extracopreal membrane oxygenation (ECMO) support, as well as the effect of different ECMO flows on lung perfusion monitored by EIT.

Detailed description

This is a monocentric obsevensional study that uses EIT to monitor lung perfusion during VV ECMO support and the effect of different ECMO flows on lung perfusion as measured by EIT. Patients on VV ECMO who meet the withdrawal criteria as determined by clinical experts will have their ECMO flow gradually reduced. EIT lung ventilation and perfusion monitoring were performed at various ECMO flows.

Interventions

None listed

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Patients aged ≥ 18 and ≤ 70 years; 2. Patients supported with VV ECMO for respiratory failure; 3. Patients are intubated and mechanically ventilated.

Exclusion criteria

1. EIT contraindications such as chest wound dressing, pacemaker installation, defibrillator, etc; 2. Patients who did not sign the informed consent form; 3. Pulmonary embolism; 4. Pneumothorax; 5. Medium to plenty of chest water; 6. Atrial fibrillation or other malignant arrhythmia leads to a decrease in cardiac output; 7. Refractory shock; 8. Severe chronic heart and lung disease has existed in the past; 9. BMI\>35 kg/m2; 10. Intra-abdominal pressure \>20mmHg.

Design outcomes

Primary

MeasureTime frameDescription
Lung perfusion at different VV ECMO flowsup to 24hourEffect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung perfusion distribution Monitored by EIT

Secondary

MeasureTime frameDescription
Lung ventilation at different VV ECMO flowsup to 24hourEffect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung ventilation distribution monitored by EIT
Lung deadspace region at different VV ECMO flowsup to 24hourEffect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung deadspace region monitored by EIT
Lung shunt region at different VV ECMO flowsup to 24hourEffect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung shunt region monitored by EIT
Lung ventilation/perfusion matching at different VV ECMO flowsup to 24hourEffect of Different VV ECMO Flows (ECMO flow at 4.5L,3.5L,2.5L,1.5L, and after ECMO withdrawal) on lung ventilation/perfusion matching monitored by EIT
Recirculation at different VV ECMO flowsup to 24hourRecirculation at different VV ECMO flows (ECMO flow at 4.5L,3.5L,2.5L,and1.5L)

Countries

China

Contacts

Primary ContactXiaobo Yang, prof.
want.tofly@aliyun.com008602785351606
Backup ContactYou Shang, prof.
you_shanghust@163.com008602785351607

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026